Diaceril

Diacerein

Method of action: Anti-Inflammatory, Antirheumatic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diaceril

Quick Facts

Property	Description
Active ingredient	Diacerein (INN)
Form	Oral capsules or tablets
Pharmacological class	Slow-acting Symptomatic Drug for Osteoarthritis (SYSADOA)
Common use	Symptomatic treatment of chronic degenerative joint conditions
Origin	Semi-synthetic (anthraquinone derivative)

What Type of Medicine is Diaceril?

Diaceril is a prescription-only medication specifically designed for the management of chronic degenerative joint conditions, functioning as a systemic anti-arthritic preparation taken orally. The drug belongs to the class of Slow-acting Symptomatic Drugs for Osteoarthritis (SYSADOA). The active agent is Diacerein, which gives the drug a distinctive, gradual therapeutic mechanism compared to conventional analgesics.

As an anthraquinone derivative, Diacerein is intended for the symptomatic treatment of osteoarthritis. This classification is clinically recognized for defining treatments that achieve delayed, yet sustained, symptomatic benefits, making Diaceril suitable for patients requiring long-term relief rather than immediate pain cessation.

Diacerein: Composition and Unique Origin

The preparation contains Diacerein as its sole active ingredient and is available in solid oral forms, such as capsules or tablets. Chemically, Diacerein is a semi-synthetic prodrug and an anthraquinone derivative that is structurally derived from the natural compound rhein.

The prodrug nature of Diacerein is a differentiating factor, as the substance itself is largely inactive until the body metabolizes it into the active compound, rhein. This process facilitates the reliable systemic delivery of the therapeutic agent after oral ingestion. This conversion provides the basis for its anti-inflammatory and modulating effects on joint tissues.

General Purpose and Mechanism Concept

The general therapeutic purpose of Diaceril is to mitigate chronic joint discomfort and help slow the degradation of cartilage. Its mechanism involves the selective inhibition of the Interleukin-1 beta (IL-1beta) pathway. IL-1beta is a critical pro-inflammatory cytokine that accelerates joint destruction. By suppressing this foundational signal, Diaceril exerts a chondroprotective influence, aiming for long-term improvement in joint function.

What side effects are possible with Diaceril?

Possible Side Effects and Safety Information

The safety profile for the active ingredient Diacerein is structured by regulatory bodies based on the frequency and system-organ class of documented adverse reactions.

Adverse Reaction Classification

The most frequently observed effects involve the Gastrointestinal Disorders system.

Classification	Adverse Reaction	System-Organ Class
Very Common (ge 1/10)	Diarrhoea, Abdominal pain	Gastrointestinal Disorders
Common (ge 1/100 to < 1/10)	Frequent bowel movements, Flatulence, Pruritus, Rash, Eczema	Gastrointestinal/Skin
Uncommon (ge 1/1000 to < 1/100)	Elevated hepatic enzymes in serum	Hepatobiliary Disorders

Serious Adverse Reactions and Key Safety Constraints

Although rare, serious adverse reactions have been documented, including acute hepatic injury and hepatitis, with reports of fatal hepatic reaction (fulminant hepatitis) particularly occurring during the first months of treatment. Severe diarrhoea is also documented as potentially leading to complications such as dehydration and electrolyte imbalance.

Time-Related Safety Patterns: Diarrhoea is typically observed early in the treatment course (within the first few weeks), often subsiding with continued use. Elevated hepatic enzyme levels are most frequently reported during the first few months.

Population-Specific Restrictions: The medicine is contraindicated in patients with a current diagnosis or history of liver disease. It is not recommended for use in individuals aged 65 years and above due to the specific risk associated with severe diarrhoea. Use is also restricted in patients with severe kidney impairment.

Overdose and Emergency Response

Overdose and when to seek help

The information provided in this section is derived strictly from official regulatory labeling and addresses the documented effects and management of Diaceril (diacerein) overdose.

Documented Manifestations and Risks

Official prescribing information states that ingesting large amounts of Diaceril will principally cause an exacerbation of the drug’s known gastrointestinal effects. The primary manifestation of overdose is severe or profuse diarrhea, often leading to loose stools and frequent bowel movements.

Critically, severe diarrhea carries the risk of significant dehydration and electrolyte disorders, such as hypokalaemia (low potassium levels), which are considered the serious systemic outcomes of overdose.

Emergency Actions

Action Required	Regulatory Instruction
Immediate Action	Treatment must be stopped upon the occurrence of severe or persistent symptoms.
Antidote Status	No specific antidote is known for diacerein overdose.
Management Focus	Treatment is symptomatic, focusing on the restoration of fluid and electrolyte balance to counteract losses from diarrhea.

When to Seek Urgent Medical Attention

Patients must immediately contact their physician or seek urgent medical attention if experiencing severe or persistent diarrhea or signs of dehydration. This is especially critical for patients aged 65 years and above, as they are at an increased risk of severe diarrhea and associated complications (dehydration, hypokalaemia).

Therapeutic Uses of Diaceril

What Diaceril Treats: Main Uses and Benefits

Diaceril is used for the symptomatic treatment of chronic degenerative joint conditions, specifically focusing on osteoarthritis affecting major joints like the hip and knee. In this therapeutic area, the medication is indicated for treating the symptoms of osteoarthritis. It is relevant in contexts where a systemic, long-term approach may be part of symptomatic management.

The primary indications include knee osteoarthritis (gonarthrosis) and hip osteoarthritis (coxarthrosis). This therapeutic domain covers patients experiencing persistent, moderate-to-severe discomfort and symptoms that interfere with daily functioning.

The medication is commonly used to help address the key symptomatic cluster of chronic osteoarthritis: persistent joint pain and functional stiffness, particularly the stiffness experienced after periods of rest. Its primary benefit is to offer symptomatic relief that helps patients cope more steadily with chronic symptoms. This symptomatic support may assist with maintaining functional stability and supports patients in achieving better day-to-day comfort and contributes to easing the overall symptom load.

“This symptomatic support helps ease the overall symptom burden associated with chronic joint conditions.”

Quick Fact: Relief for Chronic Joint Pain	Description
Symptom focus	Persistent joint pain and stiffness that interfere with daily functioning.
Clinical relevance	Used in conditions marked by heightened symptoms related to physical discomfort.
Primary benefit	Provides support that helps ease the overall symptom load for long-term comfort.

Regulatory References

European Commission Public Register

Eligibility and Restrictions for Use

Eligibility for Diaceril

Diaceril (diacerein) is restricted to the treatment of symptoms in patients with osteoarthritis of the hip or knee. Its use is subject to strict eligibility rules due to the risk of severe diarrhea and potential liver problems.

Populations Who Must Not Use Diaceril (Contraindicated):

Patients with current and/or a history of liver disease.
Patients with known hypersensitivity to diacerein, its excipients, or other anthraquinone derivatives.
Patients with active inflammatory organic bowel disease (e.g., Crohn's disease, ulcerative colitis), intestinal obstruction, or abdominal pain syndromes of indeterminate etiology.

Populations Where Use is Not Recommended or Restricted:

Population Category	Eligibility Status	Reason/Restriction
Older Adults (65 years and above)	Not Recommended	Increased risk of severe diarrhea, dehydration, and electrolyte disorders.
Pediatric Patients (under 15 years)	Not Recommended	Safety and efficacy have not been established.
Pregnancy/Lactation	Not Recommended	Due to insufficient clinical data.
Renal Impairment	Requires Caution	Dose adjustment may be needed in severe impairment (creatinine clearance < 30 ml/min).
Rapidly Progressive Hip OA	Not Recommended	May have a weaker treatment response.

Use of laxatives concurrently with Diaceril must be avoided. Treatment should be stopped immediately if diarrhea occurs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diaceril (Diacerein) has specific documented interactions with other medicines and products, largely centered on gastrointestinal effects, electrolyte balance, and drug absorption.

Contraindicated Combinations and Precautions

Co-administration with laxatives should be avoided entirely due to the potential for severe diarrhea, dehydration, and subsequent hypokalemia (low potassium).

Caution is required when Diaceril is used with diuretics (specifically loop and thiazide types) or cardiac glycosides (e.g., Digoxin, Digitoxin). This is because Diacerein's potential to cause diarrhea can lead to hypokalemia, which in turn increases the risk of serious cardiac arrhythmias in patients taking these heart medications.

Pharmacokinetic and Timing Requirements

Antacids containing aluminum, calcium, or magnesium salts reduce the absorption of Diacerein. To prevent this reduction in exposure, it is officially recommended that Antacids be taken separately, with an interval of at least two hours from Diaceril dosing.

Patients should also be advised to limit or avoid alcohol consumption during treatment. Furthermore, caution is necessary when Diaceril is used concurrently with other medicinal products known to be associated with hepatic injury.

Mechanism of Action

How Diaceril Works

Diaceril (Diacerein) is a drug that undergoes biotransformation into its active metabolite, rhein, which concentrates selectively within synovial fluid and joint tissues. The mechanism of action is primarily mediated by rhein's influence on key catabolic and inflammatory pathways

.

Interleukin-1 Beta (IL-1beta) Pathway Modulation

The principal target is the Interleukin-1 beta (IL-1beta) system, a central pro-inflammatory and matrix-degrading cytokine. Rhein inhibits the IL-1beta-driven signaling cascade, which includes decreasing the synthesis of IL-1beta and suppressing the expression of its surface receptors on cells. This action modifies the kinetics of pro-inflammatory cytokine activity within the intra-articular environment.

Modulation of Extracellular Matrix Remodeling

Rhein modulates the processes governing extracellular matrix (ECM) turnover. It affects early molecular steps by decreasing the expression and activity of Matrix Metalloproteinases (MMPs)—a class of enzymes responsible for collagenolytic activity. Concurrently, rhein influences the synthesis of structural proteins, including proteoglycans and Type II collagen. This dual action alters the molecular balance that regulates tissue degradation and formation.

Dosage and Administration Information

Instruction Map: How to use Diaceril — Official Administration Guidelines

Administration Scope

Feature	Instruction
Route of administration	Oral use only.
Dosing schedule	Initial dose: 50 mg once daily for 2 to 4 weeks. Maintenance dose: 50 mg twice daily (total 100 mg per day).
Timing in relation to meals	Must be taken with food (one capsule with breakfast and one with the evening meal).
Preparation requirements	Capsules must be swallowed intact, without opening them, together with a glass of water.
Age-group administration rules	Not recommended for patients aged 65 years and above or children under 15 years.
Missed-dose rules	Do not take a double dose to make up for a forgotten dose.
Special procedural conditions	The dose must be halved (50 mg per day) in cases of severe renal insufficiency (CrCl <30 ml/min). Antacids must be separated from intake by greater than 2 hours.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral, involving a specific solid dosage form (capsule).
Frequency pattern	Titrated use, moving from once daily (initial) to twice daily (maintenance).
Use-context constraints	Food-dependent absorption; renal impairment dose reduction; restricted by age.

Resulting Procedural Structure

Official step sequence:

Start the regimen at the initial dose of 50 mg once daily taken with food.
Swallow the capsule whole with a glass of water.
After the initial 2 to 4 weeks, increase the dose to the maintenance level of 50 mg twice daily.

Connection to the overall use protocol: The official instructions establish a standardized, oral-only protocol defined by a mandatory titration phase followed by a twice-daily maintenance schedule. This structured approach links administration to meal times and sets explicit dosage rules for patients with severe renal function impairment. The protocol is intended to govern the precise method of drug delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diaceril

Evidence from Studies for Knee Osteoarthritis

Diaceril was evaluated in studies relevant to chronic knee osteoarthritis, a condition marked by functional limitations and outcomes related to physical discomfort. The research primarily involved Randomized Controlled Trials (RCTs), which compare Diaceril against a placebo or control. These studies observed responses over defined time intervals in adult patients with conditions where symptoms may vary in intensity.

Research examined multiple outcomes, focusing heavily on patient-reported outcomes describing perceived discomfort, primarily measuring changes in pain and outcomes reflecting daily functioning or activity level. Some studies also explored structural outcomes, such as monitoring physiological strain or stress like changes in joint space width over time.

Research describes patterns observed in the studies related to these outcomes reflecting daily functioning or activity level. However, findings were mixed when compared across different trials. Evidence quality varies across studies, and some authoritative reviews note that the clinical significance of measured changes is still uncertain or under discussion.

Evidence from Studies for Hip Osteoarthritis

Studies have also monitored Diaceril in research exploring short-term symptom changes for hip osteoarthritis. As with the knee, research was evaluated in adult patients experiencing conditions where symptoms may vary in intensity. The main study types have included RCTs, which research examined through both patient-reported outcomes describing perceived discomfort and monitoring joint structure.

In studies related to the hip, researchers gave particular attention to outcomes monitoring physiological strain or stress such as joint space narrowing, comparing measurements against control groups over defined time intervals. Research highlights changes measured during the study period for both pain levels and physical function. However, the body of data specifically for hip involvement is less extensive than the data available for knee involvement.

Long-Term Studies and Durability of Follow-Up

Studies have explored the longer-term outcomes related to physical discomfort of Diaceril in protocols extending up to three years (36 months), particularly when examining structural measures. These studies contribute to the broader evidence landscape by observing responses over defined time intervals that go beyond the typical short-term assessment.

Findings help contextualize how patient-reported experiences evolved in the observed populations over extended periods. However, it is important to note that long-term effects are not fully established, and limited information for long-term outcomes is available, especially for effects sustained after treatment is stopped.

Evidence in Specific Patient Groups

Diaceril was observed in adult populations, and the research so far has primarily focused on patients with symptomatic osteoarthritis, often characterized by moderate disease severity. Data for certain groups remain insufficient from dedicated research exploring the specific use of Diaceril in other distinct patient groups.

Data for certain groups remain insufficient from dedicated research exploring specific populations. Therefore, the results apply only to the populations studied in the original clinical trials.

Unanswered Questions and Areas of Uncertainty

The evidence landscape for Diaceril includes areas of uncertainty. For Diaceril, evidence quality varies across studies, and methodological issues have been noted in some analyses. This contributes to the finding that certainty remains low regarding the magnitude and consistency of the measured outcomes across all trials.

Subgroup findings are uncertain, as the evidence for certain populations is limited. Furthermore, while research contributes to understanding symptom patterns, there is still limited information on the overall clinical relevance of the structural changes observed in studies. In summary, the existing research provides context but not individual predictions, and studies help show what has been observed so far, highlighting areas where further research is ongoing or needed.

Key Studies & References

Diacerein (INN) - Annex I Summary of Product Characteristics (European Commission Public Register)

Frequently Asked Questions (FAQ)

Common questions about Diaceril (FAQ)

Q: How long does it take for Diaceril to start working?

Diaceril is officially classified as a slow-acting drug for osteoarthritis. Studies indicate that symptomatic benefits, such as pain relief, typically begin to appear after a few weeks of consistent use. Maximal clinical benefit may often be observed after approximately three months of continuous treatment, based on study observations.

Q: Can Diaceril be taken with other pain relievers?

Official regulatory documents do not specifically prohibit the combination of Diaceril with all other pain relievers. However, caution is necessary, as combining it with medicines that also have gastrointestinal side effects could potentially increase digestive issues. Before combining Diaceril with any other medication, it is important to consult a healthcare professional regarding potential risks.

Q: Does Diaceril affect your kidneys or liver?

Diaceril can affect the liver, and regulatory information states that it is contraindicated (must not be used) in patients with a current or history of liver disease due to the risk of hepatic injury. Regarding the kidneys, in cases of severe renal impairment, a dose adjustment may be necessary according to official guidance, as the medicine is mainly eliminated through the kidneys.

Q: What are the long-term effects of taking Diaceril?

Clinical trials have assessed outcomes for long-term use, particularly structural changes, with protocols extending up to three years. Regulatory documents state that efficacy and safety for extended periods are still under discussion. Therefore, treatment requires regular follow-up with a healthcare professional.

Q: Can I drink alcohol while taking Diaceril?

Caution is advised regarding alcohol consumption during treatment with Diaceril. This recommendation is given because alcohol intake may increase the risk or severity of potential adverse reactions, particularly those related to hepatic injury (liver problems), according to official safety information.

Q: Why is Diaceril used for joint pain and not other types of pain?

Diaceril is used for joint pain because its mechanism of action is specific to the processes causing joint degradation and inflammation in osteoarthritis. The drug selectively influences these internal pathways, which is different from how general, systemic painkillers work to relieve pain.

Q: Does Diaceril interact with herbal supplements?

Interactions are possible, and caution is advised. The official label requires care when Diaceril is used with any supplement or medicine associated with hepatic injury. If a supplement contains minerals like aluminum, calcium, or magnesium, official recommendations suggest separating their intake by at least two hours to maintain proper absorption of Diaceril.

Q: What is the average time before I notice an improvement with Diaceril?

As a slow-acting medicine, it takes time to achieve the full benefit. Most patients notice an initial improvement in symptoms after two to four weeks of consistent use. Maximal clinical benefit may often be observed after approximately three months of continuous treatment, based on study observations.

Q: Does Diaceril cause weight gain?

According to the official regulatory safety tables, weight gain is not listed as a Very Common, Common, or Uncommon adverse reaction. Therefore, there is no established clinical link between the use of Diaceril and weight gain.

Q: Is Diaceril the same as Tylenol or Advil?

No, Diaceril is not the same as Tylenol (acetaminophen) or Advil (ibuprofen). Regulatory documents classify Diaceril as a Slow-Acting Symptomatic Drug for Osteoarthritis (SYSADOA). Unlike the quick-acting analgesic and anti-inflammatory properties of Tylenol and Advil, Diaceril has a different chemical structure and a delayed onset of action, working to modify the joint environment over time.

Q: Does Diaceril cause stomach problems?

Yes, gastrointestinal side effects are common. The most frequently reported adverse effects in regulatory documents are diarrhea and abdominal pain, which are classified as very common. Other common symptoms include frequent bowel movements and flatulence, which usually occur early in the treatment course.

Q: Is Diaceril a steroid?

No, Diaceril is not a steroid. Official documents classify it as an anthraquinone derivative belonging to the drug class SYSADOA (Slow-Acting Symptomatic Drug for Osteoarthritis), which is chemically and pharmacologically distinct from corticosteroids (steroids).

Q: Is it normal to feel a little dizzy after starting Diaceril?

While dizziness is not listed as a common or very common side effect in the official safety profile, regulatory documents mention that effects such as dizziness or fatigue may occur in some individuals. This is mentioned as a general caution regarding possible effects that could impair the ability to drive or operate machinery.

Q: Is Diaceril known by any other names?

Yes, the official nonproprietary or generic name for the active substance is Diacerein. It is sold under various brand names around the world, though the active ingredient remains Diacerein.

Q: Will Diaceril help with my joint stiffness?

Studies and regulatory documents indicate that Diaceril is effective for the symptomatic treatment of osteoarthritis. Stiffness is a factor measured in clinical trials that evaluate the functional capacity of patients. Improvements in these functional measures have been observed as a symptomatic benefit during treatment.

Q: What happens if I stop taking Diaceril suddenly?

Diaceril is not associated with a formal withdrawal syndrome upon sudden cessation. However, based on its slow-acting nature, stopping the medicine may be followed by a gradual return of osteoarthritis symptoms over time.

Q: Is it safe to take Diaceril with a common multivitamin?

It is generally safe, but timing is important. If a multivitamin contains minerals like aluminum, calcium, or magnesium (which can act as antacids), regulatory information indicates that separation from the Diaceril dose is necessary. Official recommendations suggest a time separation between taking these products to help maintain proper absorption of the medicine.

--UNSURE--

Q: Does Diaceril make you more sensitive to the sun?

The official safety tables list pruritus (itching), rash, and eczema as common skin-related reactions. However, there is no specific mention of photosensitivity (increased sun sensitivity) in the adverse effects tables, so it is not a recognized common effect.

How should Diaceril be stored and disposed of?

Official Storage and Disposal Requirements

Diaceril (diacerein) must be stored and handled according to the instructions provided in the official regulatory labeling to ensure product stability and safety.

Item	Requirement
Storage Temperature	Store at room temperature, not exceeding 30 C (86 F).
Environmental Protection	Protect from light and moisture. Do not refrigerate or freeze.
Container Rules	Keep the medicine in its original, tightly closed container (e.g., blister pack).
Child Safety	Must be kept out of the sight and reach of children and pets.
Disposal	Do not dispose of via household waste or wastewater. Unused or expired product must be disposed of in accordance with local regulations, typically through a pharmaceutical take-back scheme.